IKZF1 mutation	B Acute Lymphoblastic Leukemia	IKZF1 mutation	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3
IKZF1 mutation	Acute Lymphocytic Leukemia	IKZF1 mutation	Acute Lymphocytic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
IKZF1 mutation	Chronic Myeloid Leukemia	IKZF1 mutation	Chronic Myeloid Leukemia	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3

IKZF1 mutation

Associations